SPDYE5: A Potential Drug Target and Biomarker for Cell Cycle Regulation

Target Name: SPDYE5

NCBI ID: G442590

SPDYE5

SPDYE5: A Potential Drug Target and Biomarker for Cell Cycle Regulation

Introduction

Sudden progressions in the cell cycle have been implicated in various diseases, including cancer. These rapid changes in the cell cycle can lead to the formation of aberrant cells, which can lead to the development of cancer. The Speedy/RINGO cell cycle regulator family member E (SPDYE5) is a protein that plays a crucial role in regulating the cell cycle. It is a key regulator of the G1 phase, which is the stage of cell growth and division where the cell prepares for cell division.

SPDYE5: Structure and Function

SPDYE5 is a 22kDa protein that is expressed in various tissues, including brain, heart, and muscle. It is a member of the Speedy/RINGO family of proteins, which are known for their role in regulating the cell cycle. The Speedy/RINGO family includes eight proteins, including SPDYE1, SPDYE2, SPDYE3, SPDYE4, SPDYE5, SPDYE6, SPDYE7, and SPDYE8. These proteins share a conserved catalytic core and a conserved N-terminal region, but they differ in their lengths and their subcellular localizations.

SPDYE5 functions as a negative regulator of the G1 phase of the cell cycle. It inhibits the G1 checkpoint, which is a critical regulatory interaction between the G1 and S phase of the cell cycle. The G1 checkpoint is a critical checkpoint that ensures that the cell has completed all the necessary preparation for cell division before it enters the S phase. Once the G1 checkpoint is passed, the cell can enter the S phase and begin the S phase of the cell cycle.

SPDYE5 inhibits the G1 checkpoint by binding to the G1-specific protein, p21. p21 is a tumor suppressor protein that is expressed in a variety of tumors, including breast cancer, lung cancer, and colon cancer. It plays a critical role in regulating the cell cycle and is a potential drug target for cancer therapy.

SPDYE5 has also been shown to regulate the expression of other genes involved in the cell cycle, including the cyclin D1 gene and the p200 subunit of the G120-associated protein kinase. These genes are involved in the regulation of the G1 phase and the G2 phase of the cell cycle, and their regulation by SPDYE5 may have implications for the development and progression of cancer.

SPDYE5 has also been shown to play a role in the regulation of cellular processes that are important for the development of cancer. For example, SPDYE5 has been shown to regulate the production of mitochondrial enzymes, which occurs in the metabolism that during the G1 phase of the cell cycle. The production of these enzymes is critical for the development of mitochondrial dysfunction, which is a hallmark of cancer.

SPDYE5 as a Drug Target

SPDYE5 has been shown to be a potential drug target for cancer therapy. Studies have shown that inhibiting SPDYE5 can lead to the inhibition of the G1 checkpoint, which is a critical regulatory interaction between the G1 and S phase of the cell cycle. This inhibition can lead to the formation of aberrant cells, which can lead to the development of cancer.

SPDYE5 has also been shown to be involved in the regulation of the production of mitochondrial enzymes, which are involved in

Protein Name: Speedy/RINGO Cell Cycle Regulator Family Member E5

The "SPDYE5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SPDYE5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets